SCHEMBL2035119

SCHEMBL2035119

CCC(OC)(OC)c1ccnc(N)n1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 4/20 0.44
TLR8 Q9NR97 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
HRH3 Q9Y5N1 5/20 0.37
HSD17B10 Q99714 1/20 0.35
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
NOS2 P35228 2/20 0.34
ROCK1 Q13464 2/20 0.33
POLB P06746 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
CCNA1 P78396 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
MAP3K14 Q99558 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032467 0.78 NUDT1 (0.49) NUDT1TLR8HRH4HRH3HSD17B10
SCHEMBL18879260 0.77 NUDT1 (0.47) NUDT1TLR8HRH4HRH3CDK2
SCHEMBL179501 0.71 NUDT1 (0.48) NUDT1TLR8HRH4HRH3HSD17B10
SCHEMBL29162742 0.71 AURKA (0.43) NUDT1HSD17B10ROCK1POLBCDK2
SCHEMBL10739690 0.71 NUDT1 (0.37) NUDT1TLR8HRH4HRH3HSD17B10
SCHEMBL3646434 0.69 NUDT1 (0.47) NUDT1TLR8HRH4HRH3CDK2
SCHEMBL19618116 0.69 TLR8 (0.45) NUDT1TLR8HRH4HRH3
SCHEMBL31728177 0.68 NUDT1 (0.46) NUDT1TLR8HRH4HRH3CDK2
SCHEMBL13955699 0.68 LOX (0.31)
SCHEMBL30230348 0.67 HSP90AA1 (0.45) NUDT1HRH4HSD17B10NOS3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516397-B1 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME (NL) 2016-07-13 EP disclosed
US-8952001-B2 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME CORP. (US) 2015-02-10 US disclosed
EP-2516397-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS MSD Oss B.V. (NL) 2012-10-31 EP disclosed
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-10-18 US disclosed
WO-2011076723-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS N.V. ORGANON (NL) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS HCN1, HCN3, HCN2 NUDT1 2048/4885TLR8 3166/4885HRH4 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.